Trem-like transcript 1 protein (TLT-1) (TLT-1)

Trem-like transcript 1 protein (TLT-1) is a type I transmembrane receptor exclusively expressed in the alpha-granules of megakaryocytes and platelets (UniProt Q86YW5). Upon platelet activation by agonists such as thrombin or collagen, TLT-1 is rapidly translocated to the cell surface where it plays a critical role in enhancing platelet aggregation and stabilizing thrombus formation by binding to fibrinogen (Washington et al., 2004, Blood). It functions as a link between hemostasis and inflammation; its soluble form (sTLT-1) is released into the circulation during activation and serves as a biomarker for platelet-mediated inflammatory responses, particularly in sepsis (Derive et al., 2012, Journal of Immunology). Therapeutic interest in TLT-1 stems from its potential as a target for anti-thrombotic and anti-inflammatory treatments, such as the TLT-1-derived peptide LR12, which modulates the TREM-1 pathway to treat acute inflammatory shocks (Gibot et al., 2014, Intensive Care Medicine). Because its expression is restricted to the platelet lineage, TLT-1 offers a unique opportunity to manage cardiovascular and inflammatory diseases with a potentially more localized and safer profile than systemic anticoagulants.

Other names

TREML1Triggering receptor expressed on myeloid cells-like transcript 1TLT1TREM-like transcript 1

Enhancement of platelet aggregation via fibrinogen binding and modulation of TREM-1-mediated inflammatory signaling through competitive inhibition by soluble forms or derived peptides.